TB Drug Accelerator (TBDA) Program

At a Glance

- Status: Active Consortium
- Year Launched: 2012
- Initiating Organization: BGMF
- Initiator Type: Nonprofit foundation
- Rare disease
- Location: International

Abstract

The TB Drug Accelerator (TBDA) Program targets the discovery of new TB drugs by collaborating on early-stage research. The long-term goal of the TBDA Program is to create a tuberculosis (TB) drug regimen that cures patients in only one month, rather than the six months now needed for treatment.

Mission

The TBDA Program aims to develop five new preclinical drug candidates with treatment-shortening potential within five years and proof of concept for a one-month, three-drug regimen within 10 years.

Consortium History

April 2012: TBDA Program launched
Financing

The program is supported by $20 million from the Bill & Melinda Gates Foundation.

Links/Social Media Feed

Homepage  http://partnerships.ifpma.org/partnership/tb-drug-accelerator-program

Sponsors & Partners

AbbVie
AstraZeneca
Bayer HealthCare
Bill & Melinda Gates Foundation
Eisai
Eli Lilly and Company
GlaxoSmithKline
MSD
Sanofi
Global Alliance for TB Drug Development (TB Alliance)
Infectious Disease Research Institute
Texas A&M University
US National Institutes of Health
Weill Medical College
Cornell University

Updated: 04/08/2016